MedTrace Logo

Monoclonal Antibody Plus Cyclophosphamide in Treating Patients With Metastatic Cancer

NCT00002482 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL

Last updated 2013-11-06

No results posted yet for this study

Summary

RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.

PURPOSE: Phase I/II trial to study the effectiveness of monoclonal antibody and cyclophosphamide in treating patients with metastatic cancer.

Conditions

  • Unspecified Adult Solid Tumor, Protocol Specific

Interventions

BIOLOGICAL

antibody therapy

BIOLOGICAL

biological therapy

BIOLOGICAL

muromonab-CD3

DRUG

cyclophosphamide

Sponsors & Collaborators

  • St. Vincent Medical Center - Los Angeles

    lead OTHER

Principal Investigators

  • Charles L. Wiseman, MD, FACP

Study Design

Purpose
TREATMENT

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1991-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00002482 on ClinicalTrials.gov